Patterns of progression in oligometastatic hormone receptor positive breast cancer after first-line systemic treatment at the metastatic stage

被引：0
|
作者：
Lacaze, Jean Louis
De Maio, Eleonora
Chaltiel, Leonor
Cabarrou, Bastien
Mounat, Thibaut Cassou
Chira, Ciprian
Glemarec, Gauthier
Massabeau, Carole
Nicolai, Vincent
Selmes, Gabrielle
机构：
[1] IUCT Oncopole, Inst Claudius Regaud, Toulouse, France
[2] IUCT Oncopole, Toulouse, France
[3] IUCT Oncopole, Inst Claudius Regaud, Dept Chirurg Oncol, Toulouse, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13054
引用
收藏
页数：1
相关论文
共 50 条
  • [41] THE METASTATIC RECEPTOR STATUS IMPACT ON FIRST-LINE TREATMENT PLANS AND CLINICAL OUTCOMES FOR RECURRENT METASTATIC BREAST CANCER
    Pannell, Allen
    BREAST, 2019, 48 : S47 - S48
  • [42] Clinical and pathological characteristics of male breast cancer at the Institute for Oncology including first-line treatment in hormone receptor positive tumours
    Serovic, K.
    Jevric, M.
    Susnjar, S.
    Spasojevic, I. Bozovic
    ANNALS OF ONCOLOGY, 2021, 32 : S74 - S74
  • [43] Quality of Life (QoL) among metastatic hormone receptor positive, HER2 negative breast cancer patients during first line systemic treatment
    Gagliato, Debora
    Araujo, Julio Antonio
    Verboski, Bianca Milena
    Marcelino, Guilherme William
    Momberg, Fabiana Nogueira
    da Silva, Gilmara Silveira
    Ciconelli, Rozana Mesquita
    Buzaid, Antonio
    CANCER RESEARCH, 2024, 84 (09)
  • [44] Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer
    Riemsma, Rob
    Forbes, C. A.
    Kessels, A.
    Lykopoulos, K.
    Amonkar, M. M.
    Rea, D. W.
    Kleijnen, J.
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 123 (01) : 9 - 24
  • [45] Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer
    Rob Riemsma
    C. A. Forbes
    A. Kessels
    K. Lykopoulos
    M. M. Amonkar
    D. W. Rea
    J. Kleijnen
    Breast Cancer Research and Treatment, 2010, 123 : 9 - 24
  • [46] Paclitaxel and doxorubicin combination in the first-line treatment of metastatic breast cancer
    Baltali, E
    Altundag, MK
    Güler, N
    Özisik, Y
    Firat, D
    Baran, I
    Tekuzman, G
    TUMORI, 2002, 88 (03) : 200 - 203
  • [47] Adding bevacizumab to paclitaxel in the first-line treatment of metastatic breast cancer
    Kevin R. Fox
    Current Oncology Reports, 2009, 11 : 5 - 7
  • [48] The role of capecitabine in first-line treatment for patients with metastatic breast cancer
    Gelmon, Karen
    Chan, Arlene
    Harbeck, Nadia
    ONCOLOGIST, 2006, 11 : 42 - 51
  • [49] First-line treatment of metastatic breast cancer with mitoxantrone, vinorelbine, and carboplatin
    Kakolyris, S
    Kourousis, C
    Koukourakis, M
    Androulakis, N
    Vamvakas, L
    Agelaki, S
    Hatzidaki, D
    Samonis, G
    Tsiftsis, D
    Georgoulias, V
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1999, 22 (06): : 568 - 572
  • [50] Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer
    Chan, A.
    Miles, D. W.
    Pivot, X.
    ANNALS OF ONCOLOGY, 2010, 21 (12) : 2305 - 2315
12345